In this article, we will list the 5 under-the-radar picks from David Einhorn that are quietly dominating 2026. Please visit 15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026 if you would like to see the extended list and the methodology behind it.
5. Acadia Healthcare Company, Inc. (NASDAQ:ACHC)
Greenlight Capital’s Stake: $59 Million
Increase in Share Price Over Past Six Months: 21%
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is a relatively recent addition to the 13F portfolio of Greenlight Capital. The fund first disclosed a stake in the company in the fourth quarter of 2024. This position comprised a little over 128,000 shares. In three of the next four quarters, the fund added to this position. Filings for the fourth quarter of 2025 show that the fund owned 4.1 million shares in the firm, up 150% compared to filings for the third quarter of 2025. The company provides behavioral healthcare services in the United States and Puerto Rico. It owns and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, as well as comprehensive treatment centers and residential treatment centers.
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is currently the largest stand-alone behavioral healthcare provider in the US, a sector with high barriers to entry. In 2025, the firm added 1,089 beds through new openings and expansions. For 2026, management has committed to adding another 400 to 600 beds. Hedge funds view this physical moat as a primary driver for long-term organic growth. As occupancy increases across these new sites, the incremental revenue is expected to drop to the bottom line at high margins since the overhead is already covered.
4. DHT Holdings, Inc. (NYSE:DHT)
Greenlight Capital’s Stake: $90 Million
Increase in Share Price Over Past Six Months: 42%
DHT Holdings, Inc. (NYSE:DHT) has been a consistent feature in the 13F portfolio of Greenlight Capital since the third quarter of 2023. Back then, this position comprised just over 2 million shares. The fund then went on a buying spree, increasing this stake by 86%, 6%, 8%, 20%, 26%, and 15% in the coming quarters. Filings for the fourth quarter of 2025 show that the fund owned close to 7.4 million shares in the firm, down slightly compared to filings for the third quarter of 2025. DHT owns and operates crude oil tankers primarily in Monaco, Singapore, Norway, and India. The company also offers technical management services.
READ MORE: Billionaire Howard Marks’ 10 Stock Picks with Huge Upside Potential.
Institutional investors are continuing to accumulate DHT Holdings, Inc. (NYSE:DHT) stock to capture a unique combination of soaring tanker rates and massive dividend payouts. The primary driver for interest in the firm is the geopolitical instability in the Middle East. With the Strait of Hormuz effectively closed due to the US-Iran conflict, the demand for VLCCs (Very Large Crude Carriers) to reroute oil has skyrocketed. In a bullish business update earlier this month, DHT revealed that 49% of its available spot days for Q2 have already been booked at an average rate of $189,500 per day. This is more than double the Q1 spot rates of $91,700. Hedge funds view this as a guaranteed earnings beat for the upcoming quarter, providing exceptional near-term visibility.
3. Victoria’s Secret & Co. (NYSE:VSCO)
Greenlight Capital’s Stake: $94 Million
Increase in Share Price Over Past Six Months: 52%
Victoria’s Secret & Co. (NYSE:VSCO) first appeared in the 13F portfolio of Greenlight Capital in the third quarter of 2023. Back then, this position comprised just a little over 67,000 shares. By the second quarter of 2022, the fund had grown this stake to more than 740,000 shares. However, by early 2023, it had sold off this holding completely. A new position in the firm was then opened in the second quarter of 2025. This comprised 887,000 shares. In the third quarter of 2025, the firm added to this stake by close to 117%, growing it to under just 2 million shares. Filings for the fourth quarter of 2025 show that the fund owned 1.7 million shares in the company, down 10% compared to filings for the previous quarter.
Victoria’s Secret & Co. (NYSE:VSCO) is being rewarded by elite investors for delivering strong financial performance. In March, the company reported adjusted EPS of $2.77, beating analyst estimates of $2.47. Revenue hit $2.27 billion, representing 8% year-over-year growth. Despite a contracting overall intimates market, the firm gained over 1% of market share in the latest quarter, signaling that the Path to Potential strategy is working. The company operates as a specialty retailer of women’s intimate, and other apparel and beauty products worldwide. It offers bras, panties, lingerie, casual sleepwear, apparel, lounge, sport, and swim products, as well as prestige fragrances and body care products.
2. Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Greenlight Capital’s Stake: $95 Million
Increase in Share Price Over Past Six Months: 58%
Institutional sentiment towards Teva Pharmaceutical Industries Limited (NYSE:TEVA) has shifted significantly following Q4 2025 earnings, which many funds used as a signal to accumulate shares. The firm reported an Adjusted EPS of $0.96, crushing the consensus estimate of $0.65. Revenue grew 11.4% year-over-year to $4.71 billion, driven by a massive surge in its innovative portfolio. For the first time, three key innovative brands collectively delivered over $1 billion in a single quarter. In March, Teva received FDA approval for PONLIMSI, a denosumab biosimilar, and filed for a biosimilar to Xolair. Hedge funds track these as high-margin catalysts that will drive revenue through 2027.
Despite Teva Pharmaceutical Industries Limited (NYSE:TEVA) stock surging over 105% in the past year, many top-tier funds believe it remains fundamentally undervalued relative to its new growth profile. In April, major brokerages raised their price targets significantly. Goldman Sachs lifted the target to $45, Bank of America to $42, and Piper Sandler to $41. Filings for the fourth quarter of 2025 show that Greenlight Capital owns just over 3 million shares in the pharma firm, down close to 20% compared to filings for the third quarter of 2025. Teva develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
1. Centene Corporation (NYSE:CNC)
Greenlight Capital’s Stake: $109 Million
Increase in Share Price Over Past Six Months: 31%
Centene Corporation (NYSE:CNC) recently posted Q1 2026 results that significantly cleared the high bar set by institutional expectations. The company delivered an Adjusted EPS of $3.37 on $49.94 billion in revenue, far exceeding analyst estimates. Management increased the 2026 full-year adjusted EPS guidance floor to greater than $3.40. Hedge funds view this as a signal that the company has finally moved past the Medicaid redetermination headwinds that plagued the sector in 2024–2025. While competitors like UnitedHealth and Humana have struggled with rising medical utilization, Centene has demonstrated better cost-containment in core niches.
The Health Benefits Ratio of Centene Corporation (NYSE:CNC) improved to 87.3% in Q1 2026. Despite lower overall Medicaid membership, Centene achieved 8% revenue growth in this segment through rate increases and state-directed payments. Hedge funds like the defensive nature of these government contracts during periods of broader economic uncertainty. In Q1 2026, the company used proceeds from divestitures to repurchase $1 billion in senior notes due in 2027. This reduced total debt to $16.4 billion, improving the debt-to-capital ratio to 43.2%.
Centene Corporation (NYSE:CNC) operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States.
While we acknowledge the potential of CNC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CNC and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 Safe Stocks to Invest In For Beginnersand 10 Best Stocks to Buy According to Nancy Pelosi.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
